viewRace Oncology Ltd

Race Oncology receives A$707,000 refund from research and development government incentive

“The increased refund for FY21 is representative of the enhanced investment we made into R&D as we expanded our Zantrene clinical and supporting programs," says MD.

Race Oncology Ltd - Race Oncology receives A$707,000 tax refund from research and development government incentive

Race Oncology Ltd (ASX:RAC)’s research and development efforts have been recognised by the Australian Government with a tax refund of A$707,557 for the 2021 financial year, generated by the Tax Office’s Research and Development Tax Incentive Refund scheme.

Receipt of the R&D tax incentive will be added to the company’s cash balance and reported in the Appendix 4C quarterly cash flow report for the March quarter.

Race Oncology managing director and CEO Phil Lynch commented: “The increased refund for FY21 is representative of the enhanced investment we made into R&D as we expanded our Zantrene clinical and supporting programs.

“We remain grateful recipients of the Australian R&D tax incentive, which is an important source of funding for Race and one that encourages us to keep our research and development work in Australia.”

About Race Oncology

Race Oncology is an ASX-listed precision oncology company with a Phase 2/3 cancer drug called Zantrene®.

Zantrene is a potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein. Overexpression of FTO has been shown to be the genetic driver of a diverse range of cancers.

Race is exploring the use of Zantrene as a new therapy for melanoma and clear cell renal cell carcinoma, which are both frequent FTO over-expressing cancers.

Read: Race Oncology raises A$29.7 million to accelerate Zantrene plans

In breakthrough preclinical research, Race has also discovered that Zantrene protects from anthracycline-induced heart damage, while in tandem acting with anthracyclines and proteasome inhibitors to improve their ability to target breast cancer. Race is evaluating this discovery.

Read: Race Oncology Ltd (ASX:RAC) extends collaborative research program with University of Newcastle for cardio-protective drug Zantrene® in cancer patients

The company also has compelling clinical data for Zantrene as a chemotherapeutic agent and is in clinical trial in Acute Myeloid Leukaemia (AML).

Read: Race Oncology reveals promising results for its chemotherapy drug

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Race Oncology Ltd named herein, including the promotion by the Company of Race Oncology Ltd in any Content on the Site, the Company receives...


Race Oncology secures governance approval for open-label Zantrene trial

Race Oncology Ltd (ASX:RAC)'s Daniel Tillett speaks to Proactive after the company secured governance approval for its open-label clinical trial of flagship drug candidate Zantrene®. The trial will study Zantrene’s efficacy in patients with extramedullary acute myeloid leukaemia (AML) or...

1 week, 2 days ago

2 min read